Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy:
- Relevant neoantigens could be identified in all evaluable patients and TG4050 induced tumor specific T cell responses against multiple of these patient-specific neoantigen targets.
- Early signs of clinical activity were observed with encouraging ongoing anti-tumor activity in the first patients under neoantigen vaccine treatment.
- Manufacturing time and drug release were compatible with the clinical treatment protocols.
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present additional positive immunogenicity and clinical data on TG4050, its individualized neoantigen cancer vaccine. TG4050 is currently being evaluated in two ongoing multicenter Phase I trials in patients with ovarian cancer and head and neck cancer. In a poster presentation, Transgene will discuss how these new data further demonstrate the ability of this neoantigen cancer vaccine to induce strong immune responses, targeting patient-specific mutations, that are expected to translate into clinical benefit for patients.
These results will be presented during a late-breaking poster session at the American Association for Cancer Research (AACR) meeting on April 12, 2022, in New Orleans, Louisiana, USA.
These results will be presented during a late-breaking poster session at the American Association for Cancer Research (AACR) meeting on April 12, 2022, in New Orleans, Louisiana, USA.
Transgene is presenting a comprehensive set of immunological data. Circulating immune cells quantification (in particular monocytes, DC, NK cells, subcells of CD8, CD4, Treg) and expression of immune checkpoints (ICOS and PD1) suggest that the vaccine is able to effectively induce innate and adaptive immune responses in patients.